S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
NASDAQ:CRSP

CRISPR Therapeutics News Headlines

$51.54
-0.69 (-1.32%)
(As of 05/16/2022 04:00 PM ET)
Add
Compare
Today's Range
$50.48
$53.14
50-Day Range
$43.23
$69.51
52-Week Range
$42.51
$169.76
Volume
1.28 million shs
Average Volume
1.55 million shs
Market Capitalization
$3.99 billion
P/E Ratio
14.28
Dividend Yield
N/A
Beta
2.05
Get CRISPR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

CRISPR Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRSP
News Sentiment

-0.41

0.48

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRSP Articles
This Week

37

3

CRSP Articles
Average Week



CRISPR Therapeutics (NASDAQ:CRSP) News Headlines Today

SourceHeadline
marketbeat.com logoCRISPR Therapeutics (NASDAQ:CRSP) PT Lowered to $122.00 at Needham & Company LLC
marketbeat.com - May 13 at 12:30 PM
marketbeat.com logoJefferies Financial Group Equities Analysts Decrease Earnings Estimates for CRISPR Therapeutics AG (NASDAQ:CRSP)
marketbeat.com - May 12 at 6:22 AM
marketbeat.com logo3 Best Life Sciences Stocks to Buy Now (CRSP)
marketbeat.com - April 8 at 12:25 PM
finance.yahoo.com logoCRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed Drugs
finance.yahoo.com - May 16 at 4:07 PM
finance.yahoo.com logoCRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer
finance.yahoo.com - May 16 at 4:07 PM
MarketBeat logoNeedham & Company LLC Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $122.00
americanbankingnews.com - May 16 at 6:06 AM
nasdaq.com logoCRISPR Therapeutics AG Shares Close the Day 12.2% Higher - Daily Wrap
nasdaq.com - May 14 at 3:55 PM
MarketBeat logoEquities Analysts Offer Predictions for CRISPR Therapeutics AG's Q2 2022 Earnings (NASDAQ:CRSP)
americanbankingnews.com - May 13 at 2:22 AM
MarketBeat logoWilliam Blair Comments on CRISPR Therapeutics AG's Q2 2022 Earnings (NASDAQ:CRSP)
americanbankingnews.com - May 13 at 2:22 AM
MarketBeat logoQ2 2022 EPS Estimates for CRISPR Therapeutics AG (NASDAQ:CRSP) Cut by Analyst
americanbankingnews.com - May 13 at 2:22 AM
MarketBeat logoCRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $99.00
americanbankingnews.com - May 12 at 4:38 AM
MarketBeat logoCRISPR Therapeutics (NASDAQ:CRSP) PT Lowered to $85.00
americanbankingnews.com - May 12 at 4:38 AM
MarketBeat logoFY2024 EPS Estimates for CRISPR Therapeutics AG Decreased by Analyst (NASDAQ:CRSP)
americanbankingnews.com - May 12 at 2:34 AM
MarketBeat logoEquities Analysts Set Expectations for CRISPR Therapeutics AG's FY2024 Earnings (NASDAQ:CRSP)
americanbankingnews.com - May 12 at 2:34 AM
MarketBeat logoChardan Capital Lowers CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $168.00
americanbankingnews.com - May 12 at 1:56 AM
seekingalpha.com logoWhy did CRISPR Therapeutics stock rise today? Speculation as acquisition target
seekingalpha.com - May 10 at 5:29 PM
seekingalpha.com logoCRISPR stock draws flurry of price target cuts following Q1 result
seekingalpha.com - May 10 at 12:28 PM
finance.yahoo.com logoCRISPR Therapeutics (CRSP) Q1 Earnings & Sales Miss Estimates
finance.yahoo.com - May 10 at 12:28 PM
finance.yahoo.com logoCRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
finance.yahoo.com - May 9 at 4:20 PM
MarketBeat logoCRISPR Therapeutics (NASDAQ:CRSP) Reaches New 52-Week Low at $46.62
americanbankingnews.com - May 8 at 3:45 AM
seekingalpha.com logoVertex: Q1 Results Solid, If Unspectacular, But Pipeline Progress Makes Bull Case
seekingalpha.com - May 7 at 12:22 AM
nasdaq.com logoFirst Week of June 24th Options Trading For CRISPR Therapeutics (CRSP)
nasdaq.com - May 6 at 2:02 PM
finance.yahoo.com logoVertex (VRTX) Q1 Earnings Lag, Sales Top, Expense View Tweaked
finance.yahoo.com - May 6 at 2:02 PM
MarketBeat logoCRISPR Therapeutics (NASDAQ:CRSP) Now Covered by Credit Suisse Group
americanbankingnews.com - May 2 at 5:40 AM
MarketBeat logoCredit Suisse Group Initiates Coverage on CRISPR Therapeutics (NASDAQ:CRSP)
americanbankingnews.com - May 2 at 5:08 AM
markets.businessinsider.com logoWhat 4 Analyst Ratings Have To Say About CRISPR Therapeutics
markets.businessinsider.com - April 28 at 2:13 PM
MarketBeat logoCRISPR Therapeutics AG (NASDAQ:CRSP) Given Average Recommendation of "Buy" by Brokerages
americanbankingnews.com - April 28 at 2:42 AM
finance.yahoo.com logo3 Ominous Reasons to Avoid This Biotech Pioneer
finance.yahoo.com - April 19 at 7:44 AM
finance.yahoo.com logoIs Now the Time to Bet on This Game-Changing Stock?
finance.yahoo.com - April 14 at 8:41 AM
finance.yahoo.com logoCRISPR Therapeutics Proposes New Appointment to the Board of Directors
finance.yahoo.com - April 12 at 4:38 PM
finance.yahoo.com logoHedge Funds Love These 10 Undervalued Mid-Cap Stocks
finance.yahoo.com - April 12 at 11:38 AM
nasdaq.com logoInteresting CRSP Put And Call Options For May 27th
nasdaq.com - April 8 at 12:00 PM
finance.yahoo.com logo3 Ultra-Popular Stocks That Could Soar 120%, 51%, and 109%, Wall Street Says
finance.yahoo.com - March 26 at 9:10 AM
finance.yahoo.com logoCathie Wood’s 10 Stock Picks for the Next 5 Years
finance.yahoo.com - March 21 at 4:25 PM
benzinga.com logoHere's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
benzinga.com - March 16 at 2:14 PM
finance.yahoo.com logoWhy CRISPR Therapeutics Stock Soared This Week
finance.yahoo.com - March 11 at 8:20 PM
finance.yahoo.com logoIntellia Stock Has Tumbled. There Are Issues With Gene-Editing Patents.
finance.yahoo.com - March 9 at 12:58 PM
finance.yahoo.com logoHarvard, MIT Win CRISPR Patent Dispute Against Berkeley
finance.yahoo.com - March 1 at 8:16 PM
bizjournals.com logoBroad Institute wins breakthrough CRISPR patent ruling
bizjournals.com - March 1 at 10:04 AM
finance.yahoo.com logoPatent Ruling Is a Setback for Gene-Editing Firms Tied to Crispr Nobelists
finance.yahoo.com - March 1 at 10:04 AM
finance.yahoo.com logo10 Innovative Stocks in Cathie Wood’s Portfolio That Failed to Impress
finance.yahoo.com - February 28 at 12:25 PM
seekingalpha.com logoCRISPR Therapeutics GAAP EPS of -$1.84 misses by $0.10, revenue of $12.9M beats by $10.65M
seekingalpha.com - February 15 at 6:15 PM
finance.yahoo.com logoCRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
finance.yahoo.com - February 15 at 6:15 PM
finance.yahoo.com logoCRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 9 at 8:09 AM
finance.yahoo.com logoWhy CRISPR Therapeutics Stock Fell 15.9% Last Month and Continues to Fall
finance.yahoo.com - February 8 at 12:06 PM
finance.yahoo.com logoCRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)
finance.yahoo.com - February 2 at 10:01 AM
finance.yahoo.com logoCrispr Therapeutics begins dosing patients in Phase 1 trial for experimental type 1 diabetes treatment
finance.yahoo.com - February 2 at 10:01 AM
finance.yahoo.com logo3 Green Flags for CRISPR Therapeutics' Future
finance.yahoo.com - January 26 at 9:30 AM
nasdaq.com logoCRISPR Therapeutics AG Common Shares (CRSP)
nasdaq.com - January 22 at 6:09 PM
finance.yahoo.com logoArlington Financial Advisors, LLC Buys FIRST TR EXCHANGE, Apple Inc, iShares MSCI All Country ...
finance.yahoo.com - January 18 at 9:57 AM
nasdaq.com logoCRSP: Investors Pumped by Unique Price Point, Intriguing Pipeline
nasdaq.com - January 9 at 8:18 AM
finance.yahoo.com logo4 Biotechs That Could Be Potential Takeover Targets in 2022
finance.yahoo.com - December 30 at 9:32 AM
nasdaq.com logoCRISPR Therapeutics (NASDAQ:CRSP) shareholders are still up 280% over 5 years despite pulling back 5.0% in the past week
nasdaq.com - December 28 at 9:26 AM
Get CRISPR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 5/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.